Repetitive Transcranial Magnetic Stimulation Inhibits Sirt1/MAO-A Signaling in the Prefrontal Cortex in a Rat Model of Depression and Cortex-derived Astrocytes

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2017 Sep 27

PMID 28948423

Citations 7

Authors

Zheng-Wu Peng

Fen Xue

Cui-Hong Zhou

Rui-Guo Zhang

Ying Wang

Ling Liu

Han-Fei Sang

Hua-Ning Wang

Qing-Rong Tan

Affiliations

Soon will be listed here.

Abstract

Repetitive transcranial magnetic stimulation (rTMS) is a useful monotherapy for depression or adjunctive therapy for resistant depression. However, the anti-depressive effects of different parameters and the underlying mechanisms remain unclear. Here, we aimed to assess the effect of rTMS with different parameters (1/5/10 Hz, 0.84/1.26 T) on the depressive-like behaviors, 5-hydroxytryptamine (5-HT), 5-HIAA (5-hydroxyindoleacetic acid) and DA and NE levels, and monoamine oxidase A (MAO-A) activity in chronic unpredictable stress-treated rats, along with the expression of sirtuin 1 (Sirt1) and MAO-A in the prefrontal cortex (PFC) and cortex-derived astrocytes from new-born rats. Moreover, the depressive-like behaviors were monitored following the transcranial injection of the Sirt1 inhibitor EX527 (1 mM) daily for 1 week. We found that rTMS treatment (5/10 Hz, 0.84/1.26 T) ameliorated depressive-like behaviors, increased 5-HT, DA and NE levels, decreased the 5-HIAA level and Sirt1 and MAO-A expression, and reduced MAO-A activity in the PFC. The depressive-like behaviors were also ameliorated after the transcranial injection of EX527. Importantly, rTMS (5/10 Hz, 0.84/1.26 T) inhibited Sirt1 and MAO-A expressions in astrocytes and Sirt1 knockdown with short hairpin RNA decreased MAO-A expression in astrocytes. These results suggest that the inhibition of Sirt1/MAO-A expression in astrocytes in the PFC may contribute to the different anti-depressive effects of rTMS with different parameters, and may also provide a novel insight into the mechanisms underlying major depressive disorder.

Citing Articles

Repetitive Transcranial Magnetic Stimulation Reduces Depressive-like Behaviors, Modifies Dendritic Plasticity, and Generates Global Epigenetic Changes in the Frontal Cortex and Hippocampus in a Rodent Model of Chronic Stress.

Meneses-San Juan D, Lamas M, Ramirez-Rodriguez G Cells. 2023; 12(16).

PMID: 37626872 PMC: 10453847. DOI: 10.3390/cells12162062.

Contribution of glial cells to the neuroprotective effects triggered by repetitive magnetic stimulation: a systematic review.

Ferreira S, Pinto N, Serrenho I, Pato M, Baltazar G Neural Regen Res. 2023; 19(1):116-123.

PMID: 37488852 PMC: 10479834. DOI: 10.4103/1673-5374.374140.

Non-Invasive Brain Stimulation Effects on Biomarkers of Tryptophan Metabolism: A Scoping Review and Meta-Analysis.

Giron C, Lin T, Kan R, Zhang B, Yau S, Kranz G Int J Mol Sci. 2022; 23(17).

PMID: 36077088 PMC: 9456364. DOI: 10.3390/ijms23179692.

The Effects of Repetitive Transcranial Magnetic Stimulation on Cognitive Impairment and the Brain Lipidome in a Cuprizone-Induced Mouse Model of Demyelination.

Zhou C, Cai M, Wang Y, Wu W, Yin Y, Wang X Front Neurosci. 2021; 15:706786.

PMID: 34335176 PMC: 8316767. DOI: 10.3389/fnins.2021.706786.

Transcranial magnetic stimulation in animal models of neurodegeneration.

Uzair M, Abualait T, Arshad M, Yoo W, Mir A, Bunyan R Neural Regen Res. 2021; 17(2):251-265.

PMID: 34269184 PMC: 8464007. DOI: 10.4103/1673-5374.317962.

References

Berlim M, Turecki G . Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry. 2007; 52(1):46-54. DOI: 10.1177/070674370705200108. View

Liu L, Zhang Q, Cai Y, Sun D, He X, Wang L . Resveratrol counteracts lipopolysaccharide-induced depressive-like behaviors via enhanced hippocampal neurogenesis. Oncotarget. 2016; 7(35):56045-56059. PMC: 5302895. DOI: 10.18632/oncotarget.11178. View

Miller A, Raison C . The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2015; 16(1):22-34. PMC: 5542678. DOI: 10.1038/nri.2015.5. View

Magistretti P . Role of glutamate in neuron-glia metabolic coupling. Am J Clin Nutr. 2009; 90(3):875S-880S. DOI: 10.3945/ajcn.2009.27462CC. View

Duman R, Monteggia L . A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006; 59(12):1116-27. DOI: 10.1016/j.biopsych.2006.02.013. View

Herrmann L, Ebmeier K . Factors modifying the efficacy of transcranial magnetic stimulation in the treatment of depression: a review. J Clin Psychiatry. 2006; 67(12):1870-6. DOI: 10.4088/jcp.v67n1206. View

Chen K, Ou X, Wu J, Shih J . Transcription factor E2F-associated phosphoprotein (EAPP), RAM2/CDCA7L/JPO2 (R1), and simian virus 40 promoter factor 1 (Sp1) cooperatively regulate glucocorticoid activation of monoamine oxidase B. Mol Pharmacol. 2010; 79(2):308-17. PMC: 3033708. DOI: 10.1124/mol.110.067439. View

Zhu H, Chen M, Yu W, Wang W, Li F, Liu W . Time-dependent changes in BDNF expression of pentylenetetrazole-induced hippocampal astrocytes in vitro. Brain Res. 2012; 1439:1-6. DOI: 10.1016/j.brainres.2011.12.035. View

Hesselberg M, Wegener G, Buchholtz P . Antidepressant efficacy of high and low frequency transcranial magnetic stimulation in the FSL/FRL genetic rat model of depression. Behav Brain Res. 2016; 314:45-51. DOI: 10.1016/j.bbr.2016.07.037. View

10.

Sapolsky R . Is impaired neurogenesis relevant to the affective symptoms of depression?. Biol Psychiatry. 2004; 56(3):137-9. DOI: 10.1016/j.biopsych.2004.04.012. View

11.

Riederer P, Konradi C, Schay V, Kienzl E, Birkmayer G, Danielczyk W . Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Adv Neurol. 1987; 45:111-8. View

12.

Youdim M, Edmondson D, Tipton K . The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006; 7(4):295-309. DOI: 10.1038/nrn1883. View

13.

Loo C, Sachdev P, Haindl W, Wen W, Mitchell P, Croker V . High (15 Hz) and low (1 Hz) frequency transcranial magnetic stimulation have different acute effects on regional cerebral blood flow in depressed patients. Psychol Med. 2003; 33(6):997-1006. DOI: 10.1017/s0033291703007955. View

14.

Song C, Wang H . Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 35(3):760-8. DOI: 10.1016/j.pnpbp.2010.06.020. View

15.

Galletly C, Gill S, Clarke P, Burton C, Fitzgerald P . A randomized trial comparing repetitive transcranial magnetic stimulation given 3 days/week and 5 days/week for the treatment of major depression: is efficacy related to the duration of treatment or the number of treatments?. Psychol Med. 2011; 42(5):981-8. DOI: 10.1017/S0033291711001760. View

16.

Houtkooper R, Pirinen E, Auwerx J . Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol. 2012; 13(4):225-238. PMC: 4872805. DOI: 10.1038/nrm3293. View

17.

Takano B, Drzezga A, Peller M, Sax I, Schwaiger M, Lee L . Short-term modulation of regional excitability and blood flow in human motor cortex following rapid-rate transcranial magnetic stimulation. Neuroimage. 2004; 23(3):849-59. DOI: 10.1016/j.neuroimage.2004.06.032. View

18.

Wong M, Licinio J . From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov. 2004; 3(2):136-51. DOI: 10.1038/nrd1303. View

19.

Kovanen L, Donner K, Partonen T . SIRT1 Polymorphisms Associate with Seasonal Weight Variation, Depressive Disorders, and Diastolic Blood Pressure in the General Population. PLoS One. 2015; 10(10):e0141001. PMC: 4624793. DOI: 10.1371/journal.pone.0141001. View

20.

Chang H, Guarente L . SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell. 2013; 153(7):1448-60. PMC: 3748806. DOI: 10.1016/j.cell.2013.05.027. View